Another patient with concomitant bladder cancer and liver metastasis demonstrated HER2 2+ on initial biopsy and HER2 3+ after radical nephroureterectomy, maintaining stable disease for 6 months before progression and subsequent death. This evidence concerns the gene ERBB2 and urinary bladder cancer.